Dudediligence.

Candel Therapeutics, Inc

CADLNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$3,790,698

4 notices · 317,692 sh

Oct 2025 to Oct 2026

Reported ·

$3,551,080

5 sales · 1 buy · $2,999,996 bought

Oct 2025 to Sep 2026

The two figures cover different periods.

All 5 reported sales carry the 10b5-1 box. Together they are 0.42% of the shares on issue.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Sep 2026N2025DJ2026FMAMJJASO2026-09-10: PAUL PETER TAK, Form 1442026-08-17: SESHU TYAGARAJAN, Form 1442026-06-29: SESHU P TYAGARAJAN, Form 1442026-06-29: FRANCESCA BARONE, Form 1442026-02-23: Manning Paul B, bought2026-06-29: Barone Francesca, sold2026-06-29: Tyagarajan Seshu, sold2026-08-17: Tyagarajan Seshu, sold2026-09-10: Tak Paul Peter, sold
under a no plan named▼ sale▲ buysize is dollars

Form 144 notices, newest first

2026-09-10PAUL PETER TAK, Chief Executive Officer$3,410,582
280,245 shplan 2026-06-11144 ↗
Form 4, 2026-09-11: sold 280,245 at $11.28 Form 4 ↗
2026-08-17SESHU TYAGARAJAN, Chief Technology Officer$82,040
7,000 shplan 2026-03-16144 ↗
Form 4, 2026-08-19: sold 7,000 at $12.00 Form 4 ↗
2026-06-29SESHU P TYAGARAJAN, Chief Technology Officer$68,530
7,000 shplan 2026-03-16144 ↗
Form 4, 2026-07-01: sold 7,000 at $10.02 Form 4 ↗
2026-06-29FRANCESCA BARONE, Chief Scientific Officer$229,546
23,447 shplan 2026-03-16144 ↗
Form 4, 2026-07-01: sold 23,447 at $10.06 Form 4 ↗